Alpha Fusion Launches Clinical Trial for Innovative Thyroid Cancer Treatment with af-001 Alpha Fusion has initiated a pivotal clinical trial for af-001, a new alpha-emitting radiopharmaceutical aimed at treating differentiated thyroid cancer patients who are RAI-naïve.

Alpha Fusion Launches Clinical Trial for Innovative Thyroid Cancer Treatment with af-001 #Japan #Tokyo #thyroid_cancer #Alpha_Fusion #af-001

Alpha Fusion and Kobe City Medical Center Propel At-211 Drug Supply Forward Alpha Fusion and Kobe City Medical Center join forces to create a domestic supply chain for the investigational drug At-211, paving the way for innovation in cancer treatment.

Alpha Fusion and Kobe City Medical Center Propel At-211 Drug Supply Forward #Japan #Kobe #Alpha_Fusion #Kobe_City_Medical_Center #At-211

Curadh and Alpha Fusion Join Forces to Innovate Astatine-211 Radiopharmaceuticals Curadh MTR Inc. and Alpha Fusion, Inc. announce a strategic partnership to advance the development of Astatine-211 radiopharmaceuticals for cancer treatment.

Curadh and Alpha Fusion Join Forces to Innovate Astatine-211 Radiopharmaceuticals #None #Astatine-211 #Alpha_Fusion #Curadh_MTR

Strategic Partnership Between Alpha Fusion and Curadh MTR: A New Era for Astatine-211 Radiopharmaceuticals Alpha Fusion, Inc. and Curadh MTR, Inc. have announced a strategic partnership to advance the global development of Astatine-211 based radiopharmaceuticals, enhancing cancer therapy options.

Strategic Partnership Between Alpha Fusion and Curadh MTR: A New Era for Astatine-211 Radiopharmaceuticals #Japan #Osaka #Astatine-211 #Alpha_Fusion #Curadh_MTR